Olmesartan Pediatric Pharmacokinetic (PK) Study
An Open-label Study of the Single-dose Pharmacokinetics of Olmesartan Medoxomil in Pediatric Patients With Hypertension
Sponsor: Daiichi Sankyo
Listed as NCT00151814, this PHASE1 trial focuses on Hypertension and remains completed. Sponsored by Daiichi Sankyo, it has been updated 10 times since 2005, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Mar 2024 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2023 — Mar 2024 [monthly]
Completed PHASE1
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE1
▶ Show 5 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Sep 2017 — Jun 2018 [monthly]
Completed PHASE1
-
Feb 2017 — Sep 2017 [monthly]
Completed PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Sep 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Daiichi Sankyo
For direct contact, visit the study record on ClinicalTrials.gov .